Plasticell, the biotechnology company using combinatorial technologies for stem cell research and the optimization of cell and gene therapy manufacturing, has announced the signing of a collaboration agreement with the National University of Ireland, Galway (NUI Galway) focused on methods of eradicating cancer stem cells. Many malignant tumors are initiated and maintained by a discrete population of tumour cells that [...]

Plasticell is pleased to announce it has been awarded the 2016 Queen’s Award for Enterprise in Innovation. The award is the UK’s highest accolade for outstanding commercial success as a result of innovation in recognition of Plasticell’s contribution to the advancement of regenerative medicine, cell and gene therapy as well as other areas of biomedical research. Dr. Yen Choo, Plasticell’s [...]

Plasticell, a biotechnology company using combinatorial cell culture technologies for optimization of cell and gene therapy manufacturing, has announced the signing of a collaboration agreement with Sphere Fluidics, a company specializing in single cell encapsulation and screening. Plasticell has used its proprietary Combinatorial Cell Culture™ (CombiCult®) platform to develop inexpensive, high-efficiency gene transduction protocols as alternatives to costly commercial transfection [...]

Plasticell, the biotechnology company specializing in stem cell differentiation, and Pierre Fabre, the 2ndlargest independent French Pharmaceutical laboratory, have today announced the signing of a collaboration agreement. The two companies will work together to discover plant-based products that enhance the metabolic function of brown adipose tissue (BAT) – also known as ‘brown fat’. Plasticell will screen Pierre Fabre’s ‘Nature Open [...]

Plasticell, the regenerative medicine company utilising its award-winning combinatorial technologies for stem cell research and in developing cell therapies, has recruited Dr Aaron Chuang to its executive management team in the role of Chief Scientific Officer (CSO). Prior to this appointment, Dr Chuang served as Research Director at the Regenerative Medicine unit of GlaxoSmithKline (GSK), where he worked for over [...]

Plasticell Limited announced today the publication of peer-reviewed scientific research that demonstrates how the company’s proprietary ‘Combinatorial Cell Culture™‘ (CombiCult®) technology allows scientists to perform and compare 10,000 embryonic stem cell differentiation experiments in parallel. The individual experiments would have required around 200 years to complete back-to-back. The paper entitled ‘Directed differentiation of embryonic stem cells using a bead-based combinatorial [...]

Progenitor Labs, the biotech company developing small molecule drugs to regenerate organs of the body, announced today it has been selected a Red Herring Top 100 Europe Finalist, a prestigious list honoring the year’s most promising private technology ventures from the European business region. The Red Herring editorial team selected the most innovative companies from a pool of hundreds in [...]

Plasticell, the biotechnology company specializing in stem cell differentiation, has today announced that it has signed a collaboration agreement with JCR Pharmaceuticals Co., Ltd. of Ashiya, Hyogo Pref., Japan, to discover custom stem cell culture media using its award-winning combinatorial stem cell technology, CombiCult®. Under the terms of the agreement, Plasticell will use its stem cell expertise to work with [...]

Plasticell, the biotechnology company developing regenerative drugs using high throughput stem cell technologies, has announced that a further family of patents, offering additional protection of its proprietary cell culture technology, Combinatorial Cell Culture™ (CombiCult®), have been granted by the US Patent Office, European Patent Office, Australian Patent Office and Intellectual Property Office of Singapore. The newly granted patents cover the [...]

Stevenage Bioscience Catalyst (SBC), the UK’s first open innovation bioscience campus, is pleased to welcome regenerative medicine companies Plasticell Ltd and Progenitor Labs as tenants. Progenitor Labs is a drug discovery spin-off from Plasticell and recently received £4m in funding from SR One, the corporate venture arm of GlaxoSmithKline (GSK). Cell therapy and regenerative medicine is a focus of SBC’s [...]

EMD Millipore, the Life Science division of Merck KGaA of Darmstadt, Germany, and Plasticell of London, UK, today announced the availability of OsteoMAX-XF™, the first fully defined, xeno-free human mesenchymal stem cell differentiation medium for the differentiation of mesenchymal stem cells into osteocytes. Mineralization can be detected in less than one week, whereas competing products that contain serum require approximately [...]

Investment from SR One, GlaxoSmithKline’s Corporate Venture Fund, will fund company’s programme to discover small molecule drugs that regenerate specific tissues of the body. Progenitor Labs Ltd (Progenitor) has announced that it has raised £4 million ($5.8million) in seed financing from SR One’s UK Fund. Progenitor is a pioneering regenerative medicine company that develops drugs to regenerate specific tissues of [...]

Plasticell, the UK stem cell differentiation specialist has licensed EMD Millipore, the Life Science Division of Merck KGaA, to distribute a superior, single-application osteogenic medium discovered using the award winning, massively parallel combinatorial screening system, CombiCult®. The osteogenic medium is serum- and xeno- free, more consistent and more potent than currently available formulations. Under the terms of the contract, [...]

Plasticell, the biotechnology company specialising in high throughput technologies for directed stem cell differentiation, has today announced that it has engaged Veritas Corporation of Tokyo as the exclusive distributor for all of its services and products, including CombiCult®, in Japan. CombiCult® breaks the major bottleneck in stem cell research and development programmes – the discovery of optimised stem cell differentiation [...]

Plasticell, the biotechnology company specialising in high throughput technologies for directed stem cell differentiation, today announced that patents for its combinatorial cell culture platform technology, CombiCult™, have been granted in the USA and Japan. Patents covering CombiCult™ have now been issued in Europe, USA, Japan, Australia and Singapore. CombiCult™ breaks the major bottleneck in stem cell research and development programmes [...]